CD80 and neoplasm: To assess the role of PD-1/PD-L1 and CD80/PD-L1 for in vivo iTreg and Teff recruitment into tumor-infiltrating lymphocytes (TILs) and tumor dLNs, we treated B16F10 melanoma bearing mice with anti-PD-1 (Rmp1-14) or anti-CD80 (1G10) mAbs that blocked their specific binding to PD-L1, and assessed tumor growth and changes in Tregs and Teffs in TILs and dLNs (Fig. 6d).